The European Bank for Reconstruction and Development (EBRD) is investing up to USD 20 million in the expansion of pharmaceutical manufacturing at NIKA PHARM, a company within ASKLEPIY Group.
The project is aimed at strengthening the company’s position in the domestic market and expanding its export potential. It also includes the expansion and modernization of production in line with international GMP standards, as well as an increase in production capacity by more than 140%, which will help reduce import dependence at the national level.
It is worth noting that in December 2021, the EBRD provided NIKA PHARM with its first loan of USD 5 million. Over the following four years, the company established local production of a number of medicines and became a market leader in several pharmaceutical segments with brands such as Rinoksil, Rinomaks, and Forsil.
Today, ASKLEPIY Group confirms its status as one of the key drivers of Uzbekistan’s pharmaceutical industry by investing in technology, quality, and the health of millions of people.
We are creating the future. Honestly. Together.
